Role of lifestyle factors on plasma homocysteine levels in Parkison's disease patients treated with levodopa

Nutritional Neuroscience

Volumn 9, Issue 1-2, 2006, Pages 11-16

  Siniscalchi, Antonio ^a   Gallelli, Luca ^b   Mercuri, Nicola B ^c   Ibbadu, Guido Ferreri ^b   De Sarro, Giovambattista ^b  

^a ANNUNZIATA HOSPITAL   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Behaviours; Coffee; Homocysteine; Parkinson's disease patients; Smoke; Vitamin

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ACETYLCYSTEINE; ANTICONVULSIVE AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; FIBRIC ACID DERIVATIVE; FOLIC ACID; HOMOCYSTEINE; INSULIN; LEVODOPA; METFORMIN; METHOTREXATE; NICOTINIC ACID; ORAL ANTIDIABETIC AGENT; PYRIDOXINE; RIBOFLAVIN; SALAZOSULFAPYRIDINE;

ABSENCE OF SIDE EFFECTS; ALCOHOL CONSUMPTION; AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; BRAIN ATHEROSCLEROSIS; BRAIN INFARCTION; CENTRAL NERVOUS SYSTEM DISEASE; CIGARETTE SMOKING; COFFEE; COGNITIVE DEFECT; DEMENTIA; DEPRESSION; DRUG COST; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG METABOLISM; FRAGILITY FRACTURE; GENETIC SUSCEPTIBILITY; HOMOZYGOSITY; HUMAN; HYPERHOMOCYSTEINEMIA; LIFESTYLE; NONHUMAN; PARKINSON DISEASE; PERIPHERAL NEUROPATHY; PHARMACOGENETICS; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REVIEW;

ANTIPARKINSON AGENTS; FOLIC ACID; HOMOCYSTEINE; LEVODOPA; LIFE STYLE; PARKINSON DISEASE; POLYMORPHISM, GENETIC; RIBOFLAVIN; VITAMIN B 6;

EID: 33745953159     PISSN: 1028415X     EISSN: 14768305     Source Type: Journal    
DOI: 10.1080/10284150600583446     Document Type: Review

References (58)

1. Aita, JF. (1982) Why patients with Parkinson's disease fall J Am Med Assoc, 247, pp. 515-516.
2. Bazzano, LA and He, J and Muntner, P and Vupputuri, S and Whelton, PK. (2003) Relationship between cigarette smoking and novel risk factors for cardiovascular disease in United States Ann Intern Med, 138, pp. 891-897.
3. Beulens, JW and Sierkasma, A and Schoafsma, G and Kok, FJ and Struys, EA and Jakobs, C and Hendriks, HF. (2005) Kinetics of Hcy metabolism after moderate alcohol consumption Alcohol Clin Exp Res, 29, pp. 739-745.
4. Blasco, C and Caballeria, J and Deulofen, R and Lligona, A and Pares, A and Lluis, JM and Gual, A and Rodes, J. (2005) Prevalence and mechanisms of hyperhomocysteinemia in chronic alcoholics Alcohol Clin Exp Res, 29, pp. 1044-1048.
5. Bostom, AG and Rosenberg, IH and Silbershatz, H and Jacques, PF and Selhub, J and D'Agostino, RB and Wilson, PW and Wolf, PA. (1999) Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: The Framingham study Ann Int Med, 131, pp. 352-355.
6. Bottiglieri, T. (1996) Folate, vitamin B12 and neuropsychiatric disorders Nutr Rev, 54, pp. 382-390.
7. Brouwer, IA and van Dusseldorp, M and Thomas, CMG and Duran, M and Hautvast, JGAJ and Eskes, TKAB and Steegers-Theunissen, RP. (1999) Low-dose folic acid supplementation decrease plasma homocysteine concentrations: A randomized trial Am J Clin Nutr, 69, pp. 99-104.
8. Cappuccio, FP and Bell, R and Perry, IJ and Gilg, J and Ueland, PM and Refsum, H and Sagnella, GA and Jeffery, S and Cook, DG. (2002) Homocysteine levels in men and woman of different ethnic and cultural background living in England Atherosclerosis, 164, pp. 95-102.
9. Clarke, R and Frost, C and Leroy, V and Collins, R. (1998) For homocysteine lowering trialists collaboration. Lowering blood homocysteine with folic acid based supplements: Meta-analysis of randomised trials Br Med J, 316, pp. 894-898.
10. D'Angelo, A and Selhub, J. (1997) Homocysteine and thrombotic disease Blood, 90, pp. 1-11.
11. Daly, D and Miller, JW and Nadeau, MR and Selhub, J. (1997) The effect of l-dopa administration and folate deficiency on plasma homocysteine concentrations in rats J Nutr Biochem, 8, pp. 634-640.
12. Dankner, R and Chetrit, A and Lubin, F and Sela, BA. (2004) Life-style habits and homocysteine levels in an elderly population Aging Clin Exp Res, 16, pp. 437-442.
13. de Bree, A and Verschuren, WM and Kromhout, D and Kluijtmans, LA and Blom, HJ. (2002) Homocysteine determinants and the evidence to what extent homocysteine determines the risk of coronary heart disease Pharmacol Rev, 54, pp. 599-618.
14. de Lau LML. Koudstaal PJ, van Meurs JBJ, Uitterlinden AG, Hofman A, Breteler MMB (2005) Methylenetetrahydrofolate reductase C677T genotype and PD Ann Neurol, 57, pp. 927-930.
15. Dedoussis, GV and Panagiotakos, DB and Chrysohoou, C and Pitsavon, C and Zampelas, A and Choumerianou, D and Stefanadis, C. (2004) Effect of interaction between adherence to a Mediterranean diet and the methylenetetrahydrofolate reductase 677C>T mutation on homocysteine concentrations in healthy adults: The ATTICA study Am J Clin Nutr, 80, pp. 849-854.
16. Diaz-Arrastia, R. (2000) Homocysteine and neurological disease Arch Neurol, 57, pp. 1422-1428.
17. Dierkes, J and Westphal, S. (2005) Effect of drugs on homocysteine concentrations Semin Vasc Med, 5, pp. 124-139.
18. Duan, W and Ladenheim, B and Cutler, RG and Kruman, II and Cadet, JL and Mattoson, MP. (2002) Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease J Neurochem, 80, pp. 101-110.
19. Fassbender, K and Mielke, O and Bertsch, T and Nafe, B and Froschen, S and Hennerici, M. (1999) Homocysteine in cerebral microangiography and microangiopathy Lancet, 353, pp. 1586-1587.
20. Fuller, RW and Perry, KW and Hemrick-Luecke, SK. (1984) Tropolone antagonism of the l-dopa-induced elevation of S-adenosylhomocysteine: S-adenosilmethionine ratio but not depletion of adrenaline in rat hypothalamus J Pharm Pharmacol, 36, pp. 419-420.
21. Gillet, MJ and Burnett, JR. (2005) Alcohol-associated severe hyperhomocysteinemia Ann Clin Biochem, 42, pp. 304-307.
22. Husemoen, LL and Thomsen, TF and Fenger, M and Jorgensen, T. (2004) Effect of lifestyle factors on plasma total homocysteine concentrations in relation to MTHFR (C677T) genotype Inter99(7) Eur J Clin Nutr, 58, pp. 1142-1150.
23. Kruger, WD and Evans, AA and Wang, L. (2000) Polymorphisms in the CBS gene associated with decreased risk of coronary artery disease and increased responsiveness to total homocysteine lowering by folic acid Mol Genet Metab, 70, pp. 53-60.
24. Kuhn, W and Roebroek, R and Blom, H and van Oppenraaij, D and Przuntek, H and Kretschmer, A and Buttner, T and Woitalla, D and Muller, T. (1998) Elevated plasma levels of homocysteine in Parkinson's disease Eur Neurol, 40, pp. 225-227.
25. Lamberti, P and Zoccolella, S and Armenise, E and Lamberti, SV and Fraddosio, A and de Mari, M and Iliceto, G and Livrea, P. (2005) Hyperhomocysteinemia in l-dopa treated Parkinson's disease patients: Effect of cobalamin and folate administration Eur J Neurol, 12, pp. 365-368.
26. Le Witt, PA and Nyholm, D. (2004) New developments in levodopa therapy Neurology, 62, pp. S9-S16.
27. McLean, RR and Jacques, PF and Selhub, J and Tucker, KL and Samelson, EJ and Broe, KE and Hannan, MT and Cupples, LA and Kiel, DP. (2004) Homocysteine as a predictive factor for hip fracture in older persons New Engl J Med, 350, pp. 2042-2049.
28. Melamed, E and Offen, D and Shirvan, A and Ziv, I. (2000) Levodopa an exotoxin or a therapeutic drug? J Neurol, 247, pp. II135-II139.
29. Miller, JW and Selhub, J and Nadeau, MR and Thomas, CA and Feldman, RG and Wolf, PA. (2003) Effect of l-dopa on plasma homocysteine in PD patients. Relationship to B-vitamin status Neurology, 60, pp. 1125-1129.
30. Miller, JW and Shukitt-Hale, B and Villalobos-Molina, R and Nadeau, MR and Selhub, J and Joseph, JA. (1997) Effect of l-dopa and the catechol-O-methyltransferase inhibitor Ro 41-0960 on sulphur amino acid metabolites in rats Clin Neuropharmacol, 20, pp. 55-66.
31. Muller, T. (2002) Dopaminergic substation in Parkinson's disease Expert Opin Pharmacother, 3, pp. 1393-1403.
32. Muller, T and Woitalla, D and Kuhn, W. (2003) Benefit of folic acid supplementation in Parkinsonian patients treated with levodopa J Neurol Neurosurg Psychiatry, 74, pp. 549.
33. Nakaso, K and Yasui, K and Kowa, H and Kusumi, M and Ueda, K and Yoshimoto, Y and Takeshima, T and Sesaki, K and Nakushima, K. (2003) Hypertrophy of IMC of carotid artery in Parkinson's disease is associated with l-dopa, homocysteine and MTHFR genotype J Neurol Sci, 207, pp. 19-23.
34. National Research Council.(1998) Dietary reference intakes for thiamine, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantotheic acid, biotin and choline. Washington, DC: National Academy Press.
35. Nurk, E and Tell, GS and Vollset, SE and Nygard, O and Refsum, H and Nilsen, RM and Ueland, PM. (2004) Changes in lifestyle and plasma total homocysteine: The Hordaland homocysteine studt Am J Clin Nutr, 79, pp. 812-819.
36. Nygard, O and Volsen, SE and Refsum, H and Stensvold, I and Tverdal, A and Nordrehaug, JE and Ueland, M and Kvale, G. (1995) Total plasma homocysteine and cardiovascular risk profile. The Hordaland homocysteine study J Am Med Assoc, 274, pp. 1526-1533.
37. Ordez, LA and Wurtman, RJ. (1974) Folic acid deficiency and methyl group metabolism in rat brain: Effects of l-dopa Arch Biochem Biophys, 160, pp. 372-376.
38. O'Suilleabhain, PE and Bottiglieri, T and Dewey, RB, Jr and Sharma, S and Diaz-Arrastia, R. (2004a) Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease Mov Disord, 19, pp. 1403-1408.
39. O'Suilleabhain, PE and Sung, V and Hernandez, C and Lacritz, L and Dewey, RB, Jr and Bottiglieri, T and Diaz-Arrastia, R. (2004b) Elevated plasma homocysteine level in patients with Parkinson disease: Motor, affective and cognitive associations Arch Neurol, 61, pp. 865-868.
40. Petra, V and Martijn, BK. (2004) A healthy lifestyle lowers homocysteine, but should we care? Am J Clin Nutr, 79, pp. 713-714.
41. Postuma, RB and Lang, AE. (2004) Homocysteine levodopa. Should Parkinson's disease patients receive preventive therapy? Neurology, 63, pp. 886-891
42. Riggs, KM and Spiro, A and Tucker, KL and Rush, D. (1996) Relations of vitamin B6, folate, and homocysteine to cognitive performance in the normative aging study Am J Clin Nutr, 63, pp. 306-314.
43. Rogers, JD and Sanchez-Saffon, A and Frol, AB and Diaz-Arrastia, R. (2003) Elevated plasma homocysteine levels in patients treated with l-dopa Arch Neurol, 60, pp. 59-64.
44. Sato, Y and Iwamoto, J and Kanoko, T and Satoh, K. (2005) Homocysteine as a predictive factor for hip fracture in elderly women with Parkinson's disease Am J Med, 118, pp. 1250-1255.
45. Sato, Y and Kaji, M and Tsuru, T and Oizumi, K. (2001) Risk factors for hip fracture among elderly patients with Parkinson's disease J Neurol Sci, 82, pp. 89-93.
46. Saw, SM and Yuan, JM and Ong, CN and Arakawa, K and Lee, HP and Coetzee, GA and Yu, MC. (2001) Genetic, dietary and other lifestyle determinants of plasma homocysteine concentrations in middle-aged and older Chinese men and woman in Singapore Am J Clin Nutr, 73, pp. 232-239.
47. Shelhub, J and Miller, JW. (1992) The pathogenesis of homocysteinemia: Interruption of the coordinate regulation by S-adenosylmethionine of the remethylation and transsulfuration of homocysteine Am J Clin Nutr, 55, pp. 131-138.
48. Siniscalchi, A. (2004) Hyperhomocysteinemia in neurologic diseases Recenti Prog Med, 95, pp. 371-375.
49. Siniscalchi, A and Mancuso, F and Gallelli, L and Ferreri Ibbadu, G and Mercuri, NB and De Sarro, G. (2005) Increase in plasma homocysteine levels induced by drug treatments in neurological patients Pharmacol Res, 52, pp. 367-375.
50. Strandhagen, E and Zetterberg, M and Aires, N and Palmer, M and Rymo, L and Blennow, K and Landaas, S and Thelle, DS. (2004) The methylenetetradydrofolate reductase C677T polymorphism is a major determinant of coffee-induced increase of plasma homocysteine: A randomized placebo controlled study Int J Mol Med, 23, pp. 811-815.
51. Taufek, HR and Bone, AH. (1980) Influence of exogenous l-3,4-dihydrohyphenylalanine (l-dopa) on the methionine and S-adenosylmethionine concentrations in the brain and other tissues Biochem Soc Trans, 8, pp. 62-63.
52. Urgert, R and van Vliet, T and Zock, PL and Katan, MB. (2000) Heavy coffee consumption and plasma homocysteine: A randomized controlled trial in healthy volunteers Am J Clin Nutr, 72, pp. 1107-1110.
53. van Meurs, JB and Dhonukshe-Rutten, RA and Pluijm, SM and van der Klift, M and de Jonge, R and Lindemans, J and de Groot, LC and Hofman, A and Witteman, JC and van Leeuwen, JP and Breteler, MM and Lips, P and Pols, HA and Uitterlinden, AG. (2004) Homocysteine levels and the risk of osteoporotic fracture New Engl J Med, 350, pp. 2033-2041.
54. Wald, DS and Bishop, L and Wald, NJ and Law, M and Hennessy, E and Weir, D and McPartlin, J and Scott, J. (2001) Randomized trial of folic acid supplementation and serum homocysteine levels Arch Intern Med, 161, pp. 695-700.
55. Woitalla, D and Kuhn, W and Muller, T. (2004) MTHFR C677T polymorphism, folic acid and hyperhomocysteinemia in levodopa treated patients with Parkinson's disease J Neural Transm Suppl, 68, pp. 15-20.
56. Yasui, K and Nakaso, K and Kowa, K and Takeshima, T and Nakashima, K. (2003) Levodopa-induced hyperhomocysteinemia in Parkinson's disease Acta Neurol Scand, 108, pp. 66-67.
57. Zoccolella, S and Lamberti, P and Armenise, E and de Mari, M and Lamberti, SV and Mastronardi, R and Fraddosio, A and Iliceto, G and Livrea, P. (2005) Plasma homocysteine levels in Parkinson's disease: Role of anti-Parkinsonian medications Parkinsonism Relat Disord, 11, pp. 131-133.
58. Zoccolella, S and Lamberti, P and Iliceto, G and Diroma, C and Armenise, E and Defazio, G and Lamberti, SV and Fraddosio, A and de Mari, M and Livrea, P. (2005) Plasma homocysteine levels in l-dopa-treated Parkinson's disease patients with cognitive dysfunctions Clin Chem Lab Med, 43, pp. 1107-1110.